Marine organisms and their associated microbes are rich in diverse chemical leads. With the development of marine biotechnology, a considerable number of research activities are focused on marine bacteria and fungi-derived bioactive compounds. Marine bacteria and fungi are ranked on the top of the hierarchy of all organisms, as they are responsible for producing a wide range of bioactive secondary metabolites with possible pharmaceutical applications. Thus, they have the potential to provide future drugs against challenging diseases, such as cancer, a range of viral diseases, malaria, and inflammation. This review aims at describing the literature on secondary metabolites that have been obtained from Scleractinian-associated organisms including bacteria, fungi, and zooxanthellae, with full coverage of the period from 1982 to 2020, as well as illustrating their biological activities and structure activity relationship (SAR). Moreover, all these compounds were filtered based on ADME analysis to determine their physicochemical properties, and 15 compounds were selected. The selected compounds were virtually investigated for potential inhibition for SARS-CoV-2 targets using molecular docking studies. Promising potential results against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and methyltransferase (nsp16) are presented.
Marine natural products have achieved great success as an important source of new lead compounds for drug discovery. The Red Sea provides enormous diversity on the biological scale in all domains of life including micro- and macro-organisms. In this review, which covers the literature to the end of 2019, we summarize the diversity of bioactive secondary metabolites derived from Red Sea micro- and macro-organisms, and discuss their biological potential whenever applicable. Moreover, the diversity of the Red Sea organisms is highlighted as well as their genomic potential. This review is a comprehensive study that compares the natural products recovered from the Red Sea in terms of ecological role and pharmacological activities.
A series of novel 3-allyl-2-iminothiazolidin-4-one derivatives (4-17) was synthesized, through the reaction of 3-allyl-2-((3,4-dichlorophenyl)imino)thiazolidin-4-one (3) with different aromatic aldehydes. The chemical stability of four representative thiazolidinone derivatives (3, 11, 13 and 14) was evaluated against γ-irradiation, at a radiation dose of 25 kGy. The compounds were found to be stable with no observed degradation in liquid chromatography–mass spectrometry (LC-MS) experiments. The synthesized thiazolidinone derivatives (3-17) were evaluated for their antimicrobial and anticancer activities. Among the tested compounds, compounds 5, 7, 8, 14 and 16 exhibited slight antibacterial activity against a multi-drug resistant Staphylococcus aureus (ATCC 43300 strain), at a concentration of 32 µg/mL. Compound 3 fully inhibited the growth of the fungal pathogen Cryptococcus neoformans, at a tested concentration of 32 µg/mL. Besides, compound 12 inhibited the biofilm formation of S. aureus (HG001 strain), with a percentage of 54% at a concentration of 64 µg/mL. Compared to the other tested compounds, compound 11 showed higher in vitro anticancer activity against melanoma and breast cancer cells, with growth inhibition values ranging from 42% to 73% at a concentration of 10 µM. Interestingly, only compounds 3, 8 and 16 showed weak cytotoxicity to murine fibroblast L929 cells, at a tested concentration of 100 µM. The other tested compounds were not cytotoxic to fibroblasts, which suggests the relative safety of the synthesized compounds to normal mammalian cells.